ProCE Banner Activity

CE / CME

ONC APPs Intensive: Adjuvant and Neoadjuvant Therapy in Early-Stage NSCLC: Best Practices for Safe and Effective Delivery of Care

Video

On-demand webcast of expert faculty presentation and best practices for treating early-stage non-small-cell lung cancer, including discussion on adjuvant vs neoadjuvant therapy and toxicity management, for advanced practice providers in oncology.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: October 30, 2024

Expiration: October 29, 2025

Share

Faculty

Tiffany Apana

Tiffany Apana, MSN, FNP-BC

Nurse Practitioner
Department of Thoracic Oncology
Moffitt Cancer Center
Tampa, Florida

Beth Sandy

Beth Sandy, MSN, CRNP, FAPO

Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC.​

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Target Audience

This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients treated with neoadjuvant and/or adjuvant therapy in early-stage NSCLC.

Program Learning Goal

This program aims to improve learners’ knowledge and competence in the management of patients treated with neoadjuvant and/or adjuvant therapy in early-stage NSCLC, including biomarker testing, application of treatment protocols, recognition and management of adverse events (AEs), and patient counseling to support informed decision-making and address barriers to care.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize recommended biomarker testing for early-stage NSCLC and the relevance of testing to treatment selection, to facilitate discussions of testing with patients

  • Create strategies for the use of neoadjuvant therapy in patients with early NSCLC, personalizing therapy selection according to evidence, expert recommendations, and individual patient factors

  • Evaluate evidence for the role of individual patient and tumor characteristics for the use of adjuvant therapy in patients with resected NSCLC

  • Define perioperative therapy in early NSCLC and its potential application and benefits

  • Use appropriate supportive care, proactive management of treatment-related toxicities, and patient counseling to address adverse events and barriers to optimal care

Disclosure

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Tiffany Apana, MSN, FNP-BC

Nurse Practitioner
Department of Thoracic Oncology
Moffitt Cancer Center
Tampa, Florida

Tiffany Apana, MSN, FNP-BC, has no relevant financial relationships to disclose.

Beth Sandy, MSN, CRNP, FAPO

Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Beth Sandy, MSN, CRNP, FAPO: consultant/advisor/speaker: Amgen, AstraZeneca, Janssen, Jazz, Lilly, Merck, Pfizer, Takeda.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 30, 2024, through October 29, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacotherapy credit.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until October 29, 2025. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.